^
CANCER:

Gastrointestinal Stromal Tumor

No biomarker
GIST
ripretinib
Sensitive: A1 - Approval
Deciphera Pharmaceuticals Press Release - 2 weeks
KIT positive
GIST
imatinib
Sensitive: A1 - Approval
PDGFRA D842V
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
GIST
sunitinib
Sensitive: A1 - Approval
PDGFRA exon 18 mutation
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
GIST
regorafenib
Sensitive: A1 - Approval
KIT expression
GIST
imatinib
Sensitive: A1 - Approval
NTRK2 fusion
GIST
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GIST
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GIST
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GIST
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
GIST
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
GIST
larotrectinib
Sensitive: A2 - Guideline
No biomarker
GIST
cabozantinib tablet
Sensitive: A2 - Guideline
PDGFRA exon 18 mutation
GIST
imatinib
Sensitive: A2 - Guideline
No biomarker
GIST
imatinib
Sensitive: A2 - Guideline
PDGFRA D842V
GIST
dasatinib
Sensitive: A2 - Guideline
No biomarker
GIST
sorafenib
Sensitive: A2 - Guideline
No biomarker
GIST
pazopanib
Sensitive: A2 - Guideline
No biomarker
GIST
nilotinib
Sensitive: A2 - Guideline
KIT mutation
GIST
ripretinib
Sensitive: B - Late Trials
PDGFRA mutation
GIST
ripretinib
Sensitive: B - Late Trials
KIT mutation
GIST
TAS-116
Sensitive: B - Late Trials
KIT exon 17 mutation
GIST
ripretinib
Sensitive: B - Late Trials
KIT exon 13 mutation
GIST
ripretinib
Sensitive: B - Late Trials
KIT exon 9 mutation
GIST
ripretinib
Sensitive: B - Late Trials
KIT exon 11 mutation
GIST
ripretinib
Sensitive: B - Late Trials
PDGFRA mutation
GIST
avapritinib
Sensitive: C2 – Inclusion Criteria
KIT mutation
GIST
avapritinib
Sensitive: C2 – Inclusion Criteria
PDGFRA mutation
GIST
imatinib
Sensitive: C2 – Inclusion Criteria
KIT exon 11 mutation
GIST
imatinib
Sensitive: C2 – Inclusion Criteria
KIT mutation
GIST
imatinib
Sensitive: C2 – Inclusion Criteria
KIT exon 11 mutation
GIST
ponatinib
Sensitive: C2 – Inclusion Criteria
PDGFRA D842V
GIST
ARO-002
Sensitive: C2 – Inclusion Criteria
KIT mutation
GIST
sunitinib + PLX9486
Sensitive: C3 – Early Trials
KIT exon 11 mutation + KIT exon 17 mutation
GIST
nilotinib
Sensitive: C3 – Early Trials
KIT exon 9 mutation
GIST
imatinib
Resistant: C3 – Early Trials
TEKT4 mutation
GIST
dasatinib
Resistant: C3 – Early Trials
SUFU mutation
GIST
dasatinib
Resistant: C3 – Early Trials
SDHC mutation
GIST
dasatinib
Sensitive: C3 – Early Trials
TMEM127 mutation
GIST
dasatinib
Sensitive: C3 – Early Trials
SRC mutation
GIST
dasatinib
Sensitive: C3 – Early Trials
TP53 mutation
GIST
dasatinib
Sensitive: C3 – Early Trials
APC mutation
GIST
dasatinib
Sensitive: C3 – Early Trials
KIT N822K
GIST
dasatinib
Sensitive: C3 – Early Trials
KIT N820Y
GIST
dasatinib
Sensitive: C3 – Early Trials
KIT V560E
GIST
imatinib
Sensitive: C3 – Early Trials
KIT V559_E561del
GIST
imatinib
Sensitive: C3 – Early Trials
KIT M552_V555delMYEV
GIST
imatinib
Sensitive: C3 – Early Trials
PDGFRA I843_D846delIMHD
GIST
imatinib
Sensitive: C3 – Early Trials
KIT W557_V559>F
GIST
imatinib
Sensitive: C3 – Early Trials
KIT W557_V559>C
GIST
imatinib
Sensitive: C3 – Early Trials
KIT exon 9 mutation
GIST
regorafenib
Sensitive: C3 – Early Trials
KIT exon 9 mutation
GIST
sunitinib
Sensitive: C3 – Early Trials
PDGFRA D842V
GIST
sunitinib
Resistant: C3 – Early Trials
KIT exon 11 mutation
GIST
nilotinib
Sensitive: C3 – Early Trials
KIT exon 9 mutation
GIST
nilotinib
Sensitive: C3 – Early Trials
KIT exon 11 mutation
GIST
sunitinib
Sensitive: C3 – Early Trials
PDGFRA D842V
GIST
imatinib
Resistant: C3 – Early Trials
CDK4 overexpression
GIST
imatinib
Sensitive: C3 – Early Trials
TP53 overexpression
GIST
imatinib
Resistant: C3 – Early Trials
MDM2 overexpression
GIST
imatinib
Resistant: C3 – Early Trials
DEPDC5 deletion
GIST
imatinib + everolimus
Sensitive: C3 – Early Trials
KIT exon 11 W557_K558delins
GIST
imatinib
Resistant: C3 – Early Trials
SDHB mutation
GIST
temozolomide
Sensitive: C3 – Early Trials
KIT exon 17 mutation
GIST
avapritinib
Resistant: C4 – Case Studies
KIT exon 11 mutation
GIST
avapritinib
Resistant: C4 – Case Studies
KIT exon 9 mutation
GIST
avapritinib
Resistant: C4 – Case Studies
BRAF V600E
GIST
sorafenib
Resistant: C4 – Case Studies
PDGFRA mutation
GIST
AZD1775
Sensitive: D – Preclinical
PDGFRA mutation
GIST
AZD1775 + avapritinib
Sensitive: D – Preclinical
KIT mutation
GIST
AZD1775 + avapritinib
Sensitive: D – Preclinical
GPR20 expression
GIST
DS-6157
Sensitive: D – Preclinical
KIT exon 11 mutation + KIT exon 17 mutation
GIST
sunitinib + IPI 493
Sensitive: D – Preclinical
KIT exon 9 mutation
GIST
IPI 493
Sensitive: D – Preclinical
KIT P577del + KIT W557Lfs*5 + KIT Y823D
GIST
PM184
Sensitive: D – Preclinical
KIT P577del + KIT W557Lfs*5 + KIT Y823D
GIST
imatinib
Resistant: D – Preclinical
KIT W557_V559delinsF
GIST
imatinib
Sensitive: D – Preclinical
KIT W557_V559delinsF
GIST
PM184
Sensitive: D – Preclinical
FGF2-H
GIST
imatinib + infigratinib
Sensitive: D – Preclinical
FGF2-H
GIST
imatinib
Resistant: D – Preclinical